NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Heartflow HTFL

Heartflow listed on Nasdaq on 8 Aug 2025 and is not in the S&P 500. It is worth $3.9 billion. Its board has 7 directors, 6 of them independent. 3 other officers are on file. At 30 Jun 2026, Bain Capital Life Sciences Investors was its largest institutional holder, with 9.8% of the company.

CEO
John C.M. Farquhar
Chair
William C. Weldon
Listed
8 Aug 2025 on Nasdaq
Headquarters
San Francisco, CA
Market cap
$3.9B
19 Nov 2026 close
Revenue
$176M
Fiscal year 2025
Price to sales
22.3
Market cap over revenue

Financials

Financial history

Twelve months to 30 Sep 2026, from Heartflow's quarterly filings.

Quarters since Jun 2024

Revenue
$239M
Up 47% on the year before
Net income
$-79M
-33.1% of revenue
Free cash flow
$-56M
Operating cash flow less capital spending
P/E
-
No profit over the last four quarters

Quarterly results

Each quarter's revenue, net income and free cash flow.

Jun 2024 to Sep 2026

$0$20M$40M$60M$80M202420252026$73M

Revenue breakdown

Heartflow's $73M of revenue, as its quarterly report splits it. Parts that are not a business, such as sales between segments, can be negative.

Quarter to Sep 2026

  • United States$69M, 94.6%
  • Rest of World$4M, 5.4%

Heartflow's market cap since August 2025

Weekly, up to 13 Nov 2026

Sep 2025NovJan 2026MarMayJulSepNov$4.3B

Board and leadership

Board and officers

1 person here also holds roles at other S&P 500 companies.

Board from the proxy filed 29 Apr 2026; officers filed up to 30 Sep 2026

NameTitleSinceIndependentCommitteesAge
Directors (7)
William C. WeldonChairIndependent · since 2014 · Nominating & Corporate Governance (chair)Former Chairman of the Board and Chief Executive Officer, Johnson & JohnsonOther boards: Fairfax Financial HoldingsChair2014YesNominating & Corporate Governance (chair)77
John C.M. FarquharChief Executive OfficerNot independent · since 2022Chief Executive Officer2022No54
Timothy C. BarabeDirectorIndependent · since 2022 · Audit (chair)Retired Chief Financial Officer and Executive Vice President, Affymetrix, Inc.Other boards: Cartesian TherapeuticsDirector2022YesAudit (chair)73
Julie A. CullivanDirectorIndependent · since 2020 · AuditFormer Chief Technology and People Officer, Forescout Technologies, Inc.Other boards: Axon EnterprisesDirector2020YesAudit60
Jeffrey C. LightcapDirectorIndependent · since 2011 · Compensation, Nominating & Corporate GovernanceSenior Managing Director, HealthCor Partners Management, L.P. and Senior Managing Director, Healthcare Venture Partners, LLCOther boards: CareView CommunicationsDirector2011YesCompensation, Nominating & Corporate Governance67
Wayne Joseph RileyDirectorIndependent · since 2021 · Audit, Compensation (chair)President, State University of New York Downstate Health Sciences UniversityAlso at HCA HealthcareOther boards: COMPASS PathwaysDirector2021YesAudit, Compensation (chair)67
Casey M. TanseyDirectorIndependent · since 2010 · Compensation, Nominating & Corporate GovernanceGeneral Partner, U.S. Venture PartnersOther boards: Inspire Medical Systems and Shoulder InnovationsDirector2010YesCompensation, Nominating & Corporate Governance68
Officers (3)
Vikram VergheseChief Financial OfficerLast filed 18 Sep 2026Chief Financial Officer
Marie L. JonesChief Accounting OfficerLast filed 10 Aug 2026Chief Accounting Officer
Campbell RogersChief Medical OfficerLast filed 21 Sep 2026Chief Medical Officer

Owners and trading

Largest institutional holders

Each fund group's share of Heartflow. Where a company has several share classes, the share is of its total value.

13F filings for the quarter to 30 Jun 2026

These five hold 38.2% of Heartflow.

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers sold $32.9 million of stock in 37 sales and bought $1.1 million in 1 purchase in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
17 Nov 2026SaleCampbell RogersChief Medical OfficerChief Medical OfficerSale36,345$1.7M
10 Nov 2026SaleJohn C.M. FarquharChief Executive OfficerChief Executive OfficerSale38,900$2.2M
9 Nov 2026SaleVikram VergheseChief Financial OfficerChief Financial OfficerSale3,587$191K
22 Oct 2026SaleCampbell RogersChief Medical OfficerChief Medical OfficerSale36,090$2.0M
12 Oct 2026SaleJohn C.M. FarquharChief Executive OfficerChief Executive OfficerSale38,900$1.9M
18 Sep 2026SaleCampbell RogersChief Medical OfficerChief Medical OfficerSale31,838$1.6M
18 Sep 2026SaleVikram VergheseChief Financial OfficerChief Financial OfficerSale16,766$851K
17 Sep 2026SaleVikram VergheseChief Financial OfficerChief Financial OfficerSale7,579$380K
15 Sep 2026SaleVikram VergheseChief Financial OfficerChief Financial OfficerSale668$33K
14 Sep 2026SaleVikram VergheseChief Financial OfficerChief Financial OfficerSale4,593$231K

Showing 10 of 38 trades

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

14 large insider sales in the last two years.

Left the company or board 0Appointed 0WARN layoff notices 0Large insider sales 14Jan 2025AprJulOctJan 2026AprJulOct

Insider sales of $1 million or more, and the largest tenth of Heartflow's insider sales.

Events, newest first

Showing 8 of 14 events

Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.